Research programme: eye disorder therapies - ExonHit Therapeutics

Drug Profile

Research programme: eye disorder therapies - ExonHit Therapeutics

Alternative Names: EHT 0203; EHT 0204; EHT 203; EHT 204

Latest Information Update: 04 Jul 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ExonHit Therapeutics
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Eye disorders

Most Recent Events

  • 19 Dec 2012 ExonHit Therapeutics has merged with InGen Biosciences to form Diaxonhit
  • 21 Aug 2009 Discontinued - Preclinical for Eye disorders in France (PO)
  • 18 Mar 2008 This programme is still in active development for Eye disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top